Patent intelligence · US
US 9364430
Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol
Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol
Patent details — US 9364430
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 14, 2016
- Expiration
- Jun 9, 2036
- Applicant
- Relmada Therapeutics, Inc.
- Claims
- 19
- CPC classes
- A61K, A61K31/485, A61K9/0053, A61K9/006
Quick answer
US 9364430 (Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol) is held by Relmada Therapeutics, Inc.. Status: granted. Granted Jun 14, 2016. Expires Jun 9, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Relmada Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/485, A61K9/0053, A61K9/006, A61K9/1635, A61K9/1676
More from Relmada Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11607407
Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use
granted -
US 10624887
Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol
granted -
US 9855226
d-methadone for the treatment of psychiatric symptoms
granted -
US 9468611
d-Methadone for the treatment of psychiatric symptoms
granted -
US 9125833
Multimodal abuse resistant and extended release opioid formulations
granted -
US 8329744
Methods of preventing the serotonin syndrome and compositions for use thereof
granted
Related coverage
Frequently asked questions
What is US patent 9364430?
US 9364430 (Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol) is held by Relmada Therapeutics, Inc.. Status: granted. Granted Jun 14, 2016. Expires Jun 9, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9364430?
Relmada Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 9364430 expire?
Our index shows an expiration date of Jun 9, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.